University of California

ACTG Announces Launch of Clinical Trial Evaluating Novel Treatment for Tuberculous Meningitis

Retrieved on: 
Thursday, December 7, 2023
TBM, Infection, NIAID, Tuberculous meningitis, Research, Vanderbilt University, DRS, University of California, Mortality, Spinal cord, Ageing, Membrane, Brain, Pyrazinamide, Linezolid, UM1, Inflammation, University, HIV, Bangladesh Technical Education Board, Tuberculosis, University of North Carolina, ACTG, Rifampicin, Pharmaceutical industry

LOS ANGELES, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IMAGINE-TBM study (Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM, also known as A5384). IMAGINE-TBM is a phase 2, randomized, open-label trial comparing a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide to the nine-month standard-of-care regimen for the treatment of tuberculous meningitis.

Key Points: 
  • IMAGINE-TBM is a phase 2, randomized, open-label trial comparing a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide to the nine-month standard-of-care regimen for the treatment of tuberculous meningitis.
  • Tuberculous meningitis is a life-threatening infectious disease that causes inflammation of the membranes that surround the brain and spinal cord.
  • Even with standard-of-care treatment, outcomes are poor, with high rates of mortality and chronic disability among those who survive.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

Beam Global Appoints Lisa Potok as Chief Financial Officer

Retrieved on: 
Thursday, December 7, 2023
Hillsdale College, CFO, CPA, Fortune 500, FTD, Business administration, University of California, SAN, University, Beam Suntory, ProFlowers, Accounting, Advertising, Growth, E-Comm, Control, Transport, Financial system

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Beam Global , (Nasdaq: BEEM , BEEMW), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, announced that Lisa Potok has joined the Beam Global executive team as chief financial officer.

Key Points: 
  • SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Beam Global , (Nasdaq: BEEM , BEEMW), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, announced that Lisa Potok has joined the Beam Global executive team as chief financial officer.
  • Ms. Potok is an innovative and strategically focused financial executive with Fortune 500, small and medium-sized company and international experience.
  • “Lisa Potok comes to us with international financial leadership experience at companies with revenues in the hundreds of millions and billions of dollars,” said Desmond Wheatley, CEO of Beam Global.
  • “I am thrilled to be joining an exciting and growing company like Beam Global,” said Lisa Potok, CFO at Beam Global.

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Retrieved on: 
Thursday, November 30, 2023
Urinary tract infection, University of California, Disease, Cystic fibrosis, Mortality, Pseudomonas aeruginosa, University, Phage therapy, Infection, Part, BOLT, Patient, NESS, KOL, Pharmaceutical industry

(University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.

Key Points: 
  • (University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.
  • Jonathan Solomon, Chief Executive Officer of BiomX, will review topline results from Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, as a potential treatment for chronic pulmonary infections caused by P. aeruginosa in CF patients.
  • BiomX is developing BX004, utilizing its proprietary BOLT platform, to address a significant unmet need facing thousands of CF patients who require new treatments to combat persistent and deadly lung infections.
  • P. aeruginosa is a main contributor to morbidity and mortality in patients with CF.

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, November 30, 2023
Infertility, Lead, Hospital, Culture, Insemination, Case Western Reserve University, Division, Woman, University of California, Society, University, National Institutes of Health, Obstetrics, Reproductive medicine, Bangladesh Technical Education Board, American College, Publication, Patient, Gynaecology, Reproductive biology, Pharmaceutical industry

Dr. Liu joins Femasys as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®.

Key Points: 
  • Dr. Liu joins Femasys as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®.
  • “With an exciting product pipeline and a culture focused on execution of the development and commercialization of differentiated women’s health procedures, Femasys stands apart in the industry,” said Dr. Liu.
  • He also served as the Division head, Reproductive Endocrinology and Infertility at the University of Cincinnati.
  • Ms. Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys, commented on the appointment of Dr. Liu, stating, “It is a great pleasure to welcome Dr. James Liu to Femasys as the Company’s next chief medical officer.

Planet Expects to Nominate Former YouTube CEO, Susan Wojcicki, for Election to the Board of Directors at Next Annual General Meeting

Retrieved on: 
Wednesday, December 20, 2023
Data Management, Aerospace, Technology, Manufacturing, Professional Services, Satellite, Telecommunications, Data Analytics, Software, Internet, Hardware, Carbon, Marketing, Senior, UCLA, AGM, University of California, Commerce, University, Bain & Company, Growth, Economics, Intel, Harvard University

Planet Labs PBC (NYSE: PL) (“Planet” or the “Company”), a leading provider of daily data and insights about Earth, today announced Susan Wojcicki is expected to be nominated by Planet’s Board of Directors (the “Board”) for election to the Board at the Company’s 2024 annual general meeting (AGM).

Key Points: 
  • Planet Labs PBC (NYSE: PL) (“Planet” or the “Company”), a leading provider of daily data and insights about Earth, today announced Susan Wojcicki is expected to be nominated by Planet’s Board of Directors (the “Board”) for election to the Board at the Company’s 2024 annual general meeting (AGM).
  • “I am delighted at the opportunity to have Susan join Planet’s Board of Directors.
  • Before Google, Ms. Wojcicki worked at Intel Corporation and served as a management consultant at consulting firms Bain & Company and R.B.
  • in Economics from University of California, Santa Cruz, and an M.B.A. from UCLA.

UC San Diego spin-off company receives MWh-scale purchase orders of their advanced sodium-ion batteries

Retrieved on: 
Tuesday, December 19, 2023
Kilowatt-hour, Multimedia, Tin, Electron, Research, University of California, LFP, ESS, SAN, Battery, University, ACCESS, Pritzker School, Doctor of Philosophy, Silicon, Sodium, Electric battery

SAN DIEGO, Dec. 19, 2023 /PRNewswire/ -- UNIGRID Battery, a University of California, San Diego spin-off startup company, announces that it has received its first commercial MWh-scale purchase orders for their advanced sodium ion batteries.

Key Points: 
  • SAN DIEGO, Dec. 19, 2023 /PRNewswire/ -- UNIGRID Battery, a University of California, San Diego spin-off startup company, announces that it has received its first commercial MWh-scale purchase orders for their advanced sodium ion batteries.
  • Due to this combination of properties, sodium ion batteries are emerging as the next big wave in battery technology.
  • Third party testing and validation on the advanced sodium ion batteries has been completed, and UNIGRID is on track to deliver MWh quantities of its advanced sodium ion batteries to customers in 2024.
  • The team is currently ramping up production in San Diego, California, in order to meet the rapidly growing interest and demand for their sodium-ion batteries.

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Retrieved on: 
Thursday, November 16, 2023
Multiple organ dysfunction syndrome, Primary biliary cholangitis, Permeability (electromagnetism), Hepatic encephalopathy, PBC, AASLD, IND, Disease, Mortality, Cirrhosis, Elafibranor, UCSF, Patient, Heart, Liver, ASK1, Caregiver, NTZ, Chronic liver disease, Cell death, MBA, MD, University, Transplant, Doctor of Philosophy, Microbiota, Fibrosis, Ipsen, University of California, European Foundation, Human, Inflammation, Pharmaceutical industry, ACLF, Hyperammonemia, Boston, Euronext

GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.

Key Points: 
  • GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.
  • ACLF is a potentially deadly, but reversible, condition in patients with chronic liver diseases, which is associated with multi-organ failure and high short-term mortality.
  • Pascal Prigent, CEO of GENFIT, commented: “During AASLD we were excited to further discuss our development strategy around our new pipeline focused on ACLF, where we believe multiple programs have the potential to transform the treatment paradigm for these patients.
  • As part of the “ACLF Day” event during AASLD, the critical need for treatment has been highlighted by leading experts in ACLF.

UC Berkeley ROAR Racers Among Top Teams to Demo Next-Gen Autonomous Racecars at CES 2024

Retrieved on: 
Friday, December 15, 2023
Technology, Engineering, Robotics, Manufacturing, Automotive, Autonomous Driving, Vehicles, Artificial Intelligence, Sports, University, Software, Education, Motor Sports, Hardware, Performance & Special Interest, Carnegie Mellon University, NSF, ARL, Reinforcement learning, Generative, Research, Safety, CES, Virtual reality, Indy Autonomous Challenge, DARPA, Perception, Synthetic media, University of California, Berkeley, ONR, ADLINK, HTC Vive, Student, VIA Technologies, Faculty, IAC, Automation, Build automation, ROAR, NXT, Simulation, University of California, Autonomous system, AI, UC, Transport, Video game, Industrial design, Indy

The University of California, Berkeley, Robot Open Autonomous Racing (ROAR) program, together with its multi-university partners comprising the AI Racing Tech team, will serve among three leading international teams to test out the next-gen Indy Autonomous Challenge (IAC) racecar.

Key Points: 
  • The University of California, Berkeley, Robot Open Autonomous Racing (ROAR) program, together with its multi-university partners comprising the AI Racing Tech team, will serve among three leading international teams to test out the next-gen Indy Autonomous Challenge (IAC) racecar.
  • The updated world’s fastest and most advanced autonomous racecar will be unveiled at CES 2024 , held January 9-12 in Las Vegas, NV.
  • Instead, the cockpit is outfitted with specialized hardware and high-performance controls to provide complete driverless operation.
  • The Indy Autonomous Challenge (IAC) organizes racing competitions among university-affiliated teams from around the world to program fully autonomous racecars and compete in a series of history-making events at iconic tracks.

San Diego Angel Conference at USD Opens 2024 SDAC VI Fund to Angel Investors as Applications for Founders Seeking Funding Close on December 19

Retrieved on: 
Friday, December 8, 2023
Finance, Consulting, Professional Services, Small Business, Start-Up, Other Education, University, Other Professional Services, Education, SDSU, Organization, University of San Diego, Investment, Learning, Social capital, USD, First Republic Bank, Brink, Conference, University of California, San Diego State University, Environment, MSF, UCSD, Financial services, Cryptocurrency, SDAC

San Diego Angel Conference at the University of San Diego (SDAC) activates angel investors and connects them with early-stage companies seeking seed funding.

Key Points: 
  • San Diego Angel Conference at the University of San Diego (SDAC) activates angel investors and connects them with early-stage companies seeking seed funding.
  • SDAC angel investors can expand their network through structured seminars, and socials, and by becoming a member of the USD President’s Club.
  • SDAC partners with 35+ organizations including University of San Diego ( USD ), San Diego State University ( SDSU ), and University of California, San Diego ( UCSD ), to drive deal flow and mentor startups.
  • SDAC Founder Mysty Rusk says, “We activate angel investors and fund companies with potential to solve some of the world’s biggest problems.

BrainChip Announces Dr. Tony Lewis as the New Chief Technology Officer

Retrieved on: 
Tuesday, November 21, 2023
Semiconductor, Hardware, Technology, Artificial Intelligence, Software, Champaign–Urbana metropolitan area, Specialization, BrainChip, University, OTCQX, Doctor of Philosophy, Qualcomm Ventures, Intelligence, ASX, HP Inc., Qualcomm, Coronavirus Scientific Advisory Board, HP, Retirement, Growth, University of California, ADR, Robotics, Government, Face, Management, Cybernetics, AI

Tony has served as a visiting or adjunct professor at the University of Arizona, the University of Illinois, Urbana-Champaign, and the University of Waterloo.

Key Points: 
  • Tony has served as a visiting or adjunct professor at the University of Arizona, the University of Illinois, Urbana-Champaign, and the University of Waterloo.
  • His entrepreneurial experience is evident in his founding of a government funded R&D company specializing in neuromorphic computing and robotics.
  • Tony has also made his mark as a startup advisor and investor, bringing his technical acumen to various innovative ventures.
  • “While it is bitter-sweet, I’m also excited that with this seamless transition to Tony and his immense experience, we will further accelerate Akida’s technology pipeline to market.”